Richard Adcock is the Chief Executive Officer and President of IMMUNITYBIO INC, a clinical-stage immunotherapy company focused on developing next-generation therapies for cancer and infectious diseases. With over three decades of experience in the biopharmaceutical industry, Adcock has a proven track record of leading successful organizations and driving innovation in the field of immunotherapy. Prior to joining IMMUNITYBIO INC, Adcock served as the President and CEO of Elan Pharmaceuticals, where he played a pivotal role in the development and commercialization of Tysabri, a breakthrough treatment for multiple sclerosis. Under his leadership, Elan Pharmaceuticals experienced significant growth and established itself as a leader in the biopharmaceutical industry. Adcock's extensive experience in executive management, strategic planning, and business development has been instrumental in his success at IMMUNITYBIO INC. As the CEO and President of IMMUNITYBIO INC, Adcock is responsible for overseeing the company's overall strategy, operations, and growth. He works closely with the company's scientific team to advance their pipeline of innovative immunotherapy treatments, with a focus on improving patient outcomes and addressing unmet medical needs. Adcock's leadership and vision have been crucial in positioning IMMUNITYBIO INC as a frontrunner in the development of novel immunotherapies, and his dedication to advancing the field of cancer treatment continues to drive the company forward.